April 13, 2015
1 min read
Save

Meta-analysis: OCT has poor specificity in detecting reactivation of wet AMD

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

OCT showed poor specificity in monitoring reactivation of neovascular age-related macular degeneration, according to a study.

“It is not recommended that OCT be used alone to detect reactivation of nAMD in patients being monitored. According to current evidence, OCT should not replace the reference standard of [fundus fluorescein angiography] for monitoring patients with nAMD,” the study authors said.

The authors conducted a systematic review and meta-analysis of eight monitoring studies involving 463 patients who underwent treatment for neovascular AMD; four studies were prospective, three studies were retrospective, and one study lacked that information.

Seven studies reported on the use of OCT (five on time-domain OCT, one on spectral-domain OCT and one on both) and one study reported on indocyanine green angiography (ICGA). No studies included a direct comparison of tests in the same patient population.

All OCT studies showed a sensitivity of 85% and specificity of 48% in detecting active neovascular AMD.

In studies reporting on TD-OCT, sensitivity was 70% and specificity was 65%.

There was insufficient data to calculate pooled sensitivity and specificity estimates for SD-OCT.

The ICGA study showed a sensitivity of 75.9% and specificity of 88% in detecting active disease.

Among the seven OCT studies, participants received anti-VEGF therapy in two studies and underwent photodynamic therapy in five. Participants in the ICGA study underwent laser photocoagulation. – by Matt Hasson

Disclosure: The authors report no relevant financial disclosures.